GlaxoSmithKline's China crisis has spooked shareholders

29th July 2014

Investigation of drug firm’s sales practices underline perils to all British companies of entering high-growth export markets

China is a honeypot for drug and cosmetic firms. Chinese consumers, hurt by a succession of contamination scandals, have little trust in domestic operators. For GlaxoSmithKline it should be a major profit centre but after its own China scandal, profits are in free-fall.

On Wednesday shareholders digested the latest decline and the pharmaceutical company was the FTSE 100’s biggest faller.

Read more at source article

Leave a Reply

Your email address will not be published.

30 − = 21

« back to posts